Drugs / TYRA-300
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05544552 | Nov 2022 → Nov 2026 expected | non-invasive bladder urothelial carcinoma | Tyra Biosciences, Inc | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06995677 | Jun 2025 → Feb 2028 expected | non-invasive bladder urothelial carcinoma | Tyra Biosciences, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT06842355 | Mar 2025 → Jan 2030 expected | achondroplasia | Tyra Biosciences, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYRA-300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544552 ↗ |
| Action | Inhibit | “a novel, potent fibroblast growth factor receptor (FGFR) 3-selective tyrosine kinase inhibitor” NCT05544552 ↗ |
| Route | Oral | “TYRA-300 is an oral” NCT05544552 ↗ |
| Target | FGFR3 | “a novel, potent fibroblast growth factor receptor (FGFR) 3-selective tyrosine kinase inhibitor” NCT05544552 ↗ |